Filings

3 documents · 7 matches

1. SLN Silence Therapeutics plc 10-Q 2025-11-06

   Item 1A. Risk Factors.

   tariffs on pharmaceuticals is uncertain due to the ongoing section 232 investigation into the sector. Several companies are exploring ways
   2 matches in this document Show context Copy citation

2. SLN Silence Therapeutics plc 10-K 2026-03-05

   Item 1. Business

   tariffs on imported pharmaceutical products; and (4) as part of the Make America Healthy Again Commission’s Strategy Report released
   2 matches in this document Show context Copy citation

3. SLN Silence Therapeutics plc 10-Q 2025-08-07

   Item 1A. Risk Factors.

   tariffs on imported pharmaceutical products; and directing certain federal agencies to enforce existing law regarding hospital and plan price transparency
   3 matches in this document Show context Copy citation